Madrigal Pharmaceuticals has commenced a rolling submission of a new drug application (NDA) seeking expedited approval from the US Food and Drug Administration (FDA) for its resmetirom to treat nonalcoholic steatohepatitis (NASH) with liver fibrosis. 

The company has already submitted most of the application to the authority and intends to file the remainder in July 2023. 

A priority review of the application will be sought by Madrigal.

In April 2023, resmetirom received a breakthrough therapy designation from the regulatory agency for this indication.

Madrigal was subsequently permitted to file individual portions of its NDA as they were finalised and awaiting completion of the full application.

Four Phase III trials of resmetirom are progressing to establish the product’s safety and efficacy in treating NASH. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Madrigal Pharmaceuticals research and development president and chief medical officer Becky Taub stated: “In the MAESTRO-NASH biopsy trial, resmetirom achieved both liver histological improvement endpoints proposed by FDA as reasonably likely to predict clinical benefit, and demonstrated a well-tolerated safety profile. 

“We believe the positive results from MAESTRO-NASH support the potential of resmetirom to become a foundational therapy for NASH with liver fibrosis. 

“The MAESTRO development programme will provide a robust data package to support the FDA’s review of the resmetirom NDA.”